Addressing the MMR Re-Vaccination Guidelines for Allogenic Bone Marrow Transplant Patients: A response to The American Society for Transplantation and Cellular Therapy 2019 Position Statement
The American Society for Transplantation and Cellular Therapy position statement on MMR prevention in immunocompromised cancer and hematopoietic cell transplantation (HCT) patients by Pergam et. al. addresses many of the concerns both providers and patients have about Measles prevention post-transplant.1 However, we are skeptical about the data regarding the safety of the MMR vaccination guidelines for post-allogenic bone marrow transplant patients as stated in this article.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Kevin Perez, Vivek V. Shah, Gary J. Schiller Source Type: research
More News: Biology | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Vaccines | Hematology | Measles | Measles Vaccine | Transplants | Vaccines